Gujarat Kidney & Super Speciality Ltd IPOGKSL

The IPO opens on 22 Dec 2025 & closes on 24 Dec 2025.

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre. Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad. Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care. It is one of the regional healthcare companies located in the central region of state of Gujarat. The Company categorize its healthcare services as secondary services (which are surgical services) and Tertiary Services (which are super speciality surgical services). The Hospital operates with a commitment to delivering high-quality healthcare through advanced medical technology and a team of highly skilled professionals. The Company established and commenced the operations of its first hospital under the name of Gujarat Kidney Hospital' at Vadodara, Gujarat in 2014 and later on expanded the bed capacity from 15 to 65 in 2018, with the establishment of 5 sub-specialities in the Uro Department, viz., endourology, urologic oncology, paediatric urology, reconstructive urology, and laparoscopic urology at the Gujarat Kidney Hospital. In 2019, it set up an in-house interventional cardiology department under the name of Gujarat Heart Care Unit' for offering invasive cardiology services. In 2021, carried out its first laparoscopic radical prostatectomy at the Gujarat Kidney Hospital. The Company commenced operations of its second hospital in Godhra, Gujarat in 2023, followed by carrying its first renal transplant and first Angiography in Godhra Hospital. The Company set up 3 super-speciality departments for cardiology, urology and nephrology at the Godhra Hospital in 2023-24. In 2024, Company carried out its first retrograde intrarenal surgery (RIRS) at the Godhra Hospital. It acquired majority stake in Raj Palmland Hospital Private Limited, thereby making it the Subsidiary of the Company. In 2025, the Company has acquired Ashwini Medical Centre. Company has filed a Draft Prospectus and is planning to make IPO of 2,20,00,000 equity shares of face value of Rs 2/- each through fresh issue.

Gujarat Kidney & Super Speciality Ltd IPO will close on 24 Dec 2025.

<ul><li>Pre-eminence in renal sciences, with established sub-superspecialties in urology and strong capabilities in other specialties.</li><li>`Right-sized', full service and strategically located hospitals leading to high return on capital.</li><li>Ability to attract, train and retain quality medical professionals.</li><li>Investment in infrastructure, processes and clinical excellence driving affordability, and a strong value proposition for stakeholders.</li><li>Track record of operating and financial performance and growth.</li><li>Professional management and experienced leadership.</li></ul>

<table class="table"> <thead> <tr> <th>S.No</th> <th>Promoters Name</th> <th>Pre Issue Shares</th> <th>Pre Issue Percentage</th> <th>Post Issue Shares</th> <th>Post Issue Percentage</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Pragnesh Yashwantsinh Bharpoda</td> <td>30084250</td> <td>52.92</td> <td>30084250</td> <td>38.16</td> </tr> <tr> <td>2</td> <td>Bhartiben Pragnesh Bharpoda</td> <td>8749475</td> <td>15.39</td> <td>8749475</td> <td>11.1</td> </tr> <tr> <td>3</td> <td>Yashwantsingh Motisingh Bharpo</td> <td>8750000</td> <td>15.39</td> <td>8750000</td> <td>11.1</td> </tr> <tr> <td>4</td> <td>Anitaben Yashwantsinh Bharpoda</td> <td>8750000</td> <td>15.39</td> <td>8750000</td> <td>11.1</td> </tr> <tr> <td>5</td> <td>Nikita Yashvantsinh Bharpoda</td> <td>175</td> <td>---</td> <td>175</td> <td>---</td> </tr> </tbody> </table>

<ul><li>The company proposes to use a portion of the Net Proceeds from the Issue for acquisition of Parekhs Hospital Private Limited, following which the Company will be responsible for overseeing and managing the Parekhs Hospital. Its may face difficulties in completing the acquisition within the terms mentioned in term sheet, affecting the company future plans and prospects.</li><li>The Company proposes to utilise a portion of the Net Proceeds from the Issue towards making part-payment of purchase consideration for the acquisition of Ashwini Medical Centre, pursuant to the Acquisition Agreement. In case of delay in raising funds from the Issue, its may face challenges in paying the consideration to sellers of Ashwini Medical Centre.</li><li>The company proposed plans with respect to funding the capital expenditure requirement for construction of new hospital are subject to the risk of unanticipated delays in obtaining approvals and implementation which may adversely affect its business and results of operations. Further, the company are yet to place orders for such capital expenditure requirements. There is no assurance that its would be able to source such capital expenditure requirements in a timely manner or at commercially acceptable prices, which could adversely affect the company expansion plans. Its may be unsuccessful in implementing the company growth plans of expansion in Gujarat, India in a timely manner or at all, which may have an adverse effect on its business, financial condition and results of operations. Furthermore, the proposed construction of the new hospital is planned to be carried out on leased land, which includes potential challenges or risks related to the terms of lease arrangement, could have adverse effect on the company business, financial position, and results of operations.</li><li>The Company has acquired Harmony Medicare Private Limited, subsequent to the three month period ended June 30, 2025. As its Company and Harmony Medicare Private Limited were separate entities operating independently from each other prior to June 30, 2025, the Restated Financial Statements does not include the financial information pertaining the said acquisition. Hence, the company Restated Financial Statements for the three month period ended June 30, 2025 and the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023, are not analogous and comparable to any future financial results/statements that its may prepare.</li><li>The company have assumed customary liabilities pursuant to its recent acquisitions. Any liabilities beyond the company estimates may materially and adversely impact its business, financial condition, cash flows, results of operations and the trading price of the company Equity Shares.</li><li>The company hospitals face potential reputational damage and financial consequences from any failure to provide Quality medical treatment or service. Additionally, its are exposed to operational, reputational, and legal risks, including malpractice or medical negligence claims, which could adversely impact the company reputation, operations, and financial stability.</li><li>Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval</li><li>If the company fail to achieve favourable pricing on medical consumables, pharmacy items, drugs, and surgical instruments from its suppliers or are unable to pass on any cost increases to the company payers, its profitability could be materially and adversely affected.</li><li>The company Promoters have extended personal guarantees with respect to loan facilities availed by its Company. Revocation of these personal guarantees may adversely affect the company business operations and financial condition.</li><li>Some of the company doctors are not its employees. If such doctors discontinue their association with the company or are unable to provide their services at its centres or hospitals for any reason or if the company are unable to attract or retain such doctors and other healthcare professionals, its business and results of operations may be materially and adversely affected.</li><li>The company Directors does not have any prior experience of being a director in any other listed company in India and this may present certain potential challenges for the Company and in the event of any material non-compliance where its Directors are held liable and responsible, the company may have to appoint new directors.</li><li>Various challenges currently faced by the healthcare industry in India may adversely affect the company business, results of operations and financial condition.</li><li>We face competition from other healthcare service providers. If we are unable to compete effectively, our business, results of operations and cash flows may be materially and adversely affected.</li><li>There may have been certain instances of irregularities, discrepancies and non-compliances with respect to certain corporate actions taken by our Company in the past. Consequently, we may be subject to regulatory actions and penalties.</li><li>The company subsidiary Raj Palmland Hospital Private Limited has experienced negative cash flow in the past and may continue to does so in the future, which could have a material adverse effect on the company business, prospects, financial condition, cash flows and results of operations.</li><li>The Company has applied for registration of trademark in its name. Until such registration is granted, its Company may not be able to prevent unauthorised use of such trademark by third parties, which may lead to the dilution of the company goodwill.</li><li>There have been certain instances of delays and delay in filings of statutory returns in payment of statutory dues by the Company in the past. Any failure or delay in payment of such statutory dues may expose its to statutory and regulatory action, as well as significant penalties, and may adversely impact the company business, results of operations, cash flows and financial condition.</li><li>There are outstanding litigations involving the Company, Promoters and Directors, if determined adversely, may adversely affect its business and financial condition.</li><li>The company utilize a portion of the Net Proceeds to undertake inorganic growth for which the target may not be identified. In the event that its Net Proceeds to be utilized towards inorganic growth initiatives are insufficient for the cost of the company proposed inorganic acquisition, its may have to seek alternative forms of funding.</li><li>Acquisitions, strategic investments, partnerships or alliances may be difficult to integrate, and may adversely affect the company business, financial condition and results of operations.</li><li>In addition to the company existing indebtedness for its existing operations, the company may incur further indebtedness during the course of business. Its cannot assure that the company would be able to service its existing and/ or additional indebtedness.</li><li>A downgrade in ratings of the Company, may affect the trading price of the Equity Shares.</li><li>The company are vulnerable to failures of its information technology system, which could adversely affect the company business.</li><li>The company inability to meet its obligations, including financial and other covenants under the company debt financing arrangements could adversely affect its business, financial condition, cash flows and results of operations.</li><li>The Company has issued Equity Shares in the last one year at a price which may be lower that of the Issue Price.</li><li>The company ability to pay dividends in the future will depends on the company earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of its financing arrangements.</li><li>The company Promoters, Directors, Key Managerial Personnel and Senior Management have interests in its Company other than reimbursement of expenses incurred or normal remuneration or benefits.</li><li>Fraud or misconduct by the company employees could adversely affect its reputation, business, results of operations and financial condition.</li><li>The company Promoters and members of the Promoter Group have significant control over the Company and have the ability to direct its business and affairs; their interests may conflict with your interests as a shareholder.</li><li>The company have certain contingent liabilities and its financial condition and profitability may be adversely affected if any of these contingent liabilities materialize.</li><li>Some of the company Promoters and Directors may have interest in entities or one or more ventures. Such ventures and its Subsidiaries, and entities controlled by the company he care engaged in a similar line of business as its Company and this may result in conflict of interest with the company.</li><li>The company may require additional funding to finance its operations, which may not be available on terms acceptable to the company, or at all, and if its are unable to raise funds, the value of your investment in the company may be negatively impacted.</li><li>If the company are unable to establish and maintain an effective internal control, its business and reputation could be adversely affected.</li><li>The company funding requirements and proposed deployment of the Net Proceeds of the Issue is based on management discretion and has not been appraised by a bank or a financial institution and if there are any delays or cost overruns, its business, cash flows, financial condition and results of operations may be adversely affected.</li><li>Significant differences exist between Ind AS used to prepare the company financial information and other accounting principles, such as U.S. GAAP and IFRS, which may affect investors' assessments of its Company's financial condition.</li><li>The average cost of acquisition of Equity Shares held by the company Promoters could be lower than the Issue Price.</li><li>There have been instances in the past, wherein insufficient stamp duty was paid while executing certain agreements during its ordinary course of operations. Any insufficient stamp duty may impact the enforceability of agreements executed by the Company.</li><li>The company may not be able to maintain profitability in the future due to unforeseen reasons, market fluctuations and other external factors beyond its control.</li><li>The company are exposed to risks relating to the recovery of Business Transfer Collectables arising pursuant to the acquisition of M/s. Gujarat Kidney and Superspeciality Hospital.</li><li>This Red Herring Prospectus contains information from an industry report prepared by D&B India, commissioned by the company for the purpose of the Issue for an agreed fee.</li><li>The company Equity Shares have never been publicly traded, and after the Issue, the Equity Shares may experience price and volume fluctuations, and an active trading market for the Equity Shares may not develop. Further, the Issue Price may not be indicative of the market price of the Equity Shares after the Issue.</li><li>QIBs and Non-Institutional Bidders are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid, and Retail Individual Bidders are not permitted to withdraw their Bids after Bid/Issue Closing Date.</li><li>Fluctuations in the exchange rate between the Indian Rupee and foreign currencies may have an adverse effect on the value of the company Equity Shares, independent of its operating results.</li><li>There is no guarantee that the company Equity Shares will be listed on BSE and NSE in a timely manner or at all.</li><li>The requirements of being a listed company may strain its resources.</li><li>Holders of Equity Shares may be restricted in their ability to exercise pre-emptive rights under Indian law and thereby may suffer future dilution of their ownership position.</li><li>Any future issuance of Equity Shares or convertible securities or other equity linked securities by the Company may dilute your shareholding and sales of the Equity Shares by its major shareholders may adversely affect the trading price of the Equity Shares.</li><li>Foreign investors are subject to foreign investment restrictions under Indian laws that may limit the company ability to attract foreign investors, which may have a material adverse impact on the market price of the Equity Shares.</li><li>Rights of shareholders of companies under Indian law may be more limited than under the laws of other jurisdictions.</li><li>Investors may be subject to Indian taxes arising out of capital gains on the sale of the Equity Shares.</li><li>A third party could be prevented from acquiring control of the Company because of anti-takeover provisions under Indian law.</li><li>Subsequent to the listing of the Equity Shares, the company may be subject to pre-emptive surveillance measures, such as the Additional Surveillance Measures and the Graded Surveillance Measures by the Stock Exchanges in order to enhance the integrity of the market and safeguard the interest of investors.</li></ul>

The Issue type of Gujarat Kidney & Super Speciality Ltd is Book Building.

The minimum application for shares of Gujarat Kidney & Super Speciality Ltd is 128.

The total shares issue of Gujarat Kidney & Super Speciality Ltd is 22000000.

Initial public offering of 2,20,00,000 equity shares of face value of Rs. 2 each ("Equity Shares") of the company for cash at a price of Rs. 108-Rs. 114 per equity share (including a share premium of Rs. 106-Rs. 112 per equity share) ("Issue Price") aggregating to Rs. 237.6-Rs. 250.80 crores ("Issue"). The issue shall constituted 27.90% of the post-issue paid-up equity share capital of the company. The face value of equity shares is ?2 each. the issue price was 57 times the face value of the equity shares. Bids can be made for a minimum of 128 equity shares and in multiples of 128 equity shares thereafter.